Literature DB >> 35192190

Hepatectomy for liver metastases from cervical cancer with portal vein tumor thrombosis: a case report.

Mai Nakamura1, Kyoji Ito1, Nobuyuki Takemura2, Fuminori Mihara1, Norihiro Kokudo1.   

Abstract

The prognosis of patients with liver metastasis of cervical cancer is poor with an extremely short survival period, and there have been no reports of cervical cancer complicated by portal vein tumor thrombosis (PVTT). We report a case of cervical cancer developing liver metastasis with PVTT. A 49-year-old woman developed liver metastasis from cervical cancer with PVTT. The primary tumor was locally controlled with multidisciplinary treatment, including systemic therapy, surgical resection, and radiation. However, her follow-up abdominal computed tomography results showed two irregular tumors in the liver's segments 2 and 6. From the latter lesion, a low-density filling defect extended to the posterior branch of the portal vein, suggesting PVTT. Hepatectomy of the two metastases was performed to prevent portal vein obstruction during subsequent chemotherapy. Pathological analysis revealed metastatic squamous cell carcinoma from cervical cancer that developed a tumor thrombus at the posterior branch of the portal vein. The patient received adjuvant chemotherapy, but died 10 months after surgery for recurrent liver metastasis. We present the first case of liver resection for liver metastasis from cervical cancer with PVTT. Although cervical cancer with PVTT is associated with a poor prognosis, surgical resection is a feasible option for preventing portal vein obstruction during subsequent chemotherapy.
© 2022. Japanese Society of Gastroenterology.

Entities:  

Keywords:  Cervical cancer; Hepatectomy; Liver metastasis; Portal vein tumor thrombosis

Mesh:

Year:  2022        PMID: 35192190     DOI: 10.1007/s12328-022-01603-x

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  1 in total

1.  Hepatic Resection for Liver Metastases from Cervical Cancer Is Safe and May Have Survival Benefit.

Authors:  Nicolae Bacalbasa; Irina Balescu; Simona Dima; Irinel Popescu
Journal:  Anticancer Res       Date:  2016-06       Impact factor: 2.480

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.